FindTrial
Sign In

Intelligent Malignancy Analysis and Targeted Treatment Assessment of Skin Squamous Cell Carcinoma Based on Multiplex Immunofluorescence

Intelligent Malignancy Analysis and Targeted Treatment Assessment of Skin Squamous Cell Carcinoma Based on Multiplex Immunofluorescence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094186
Enrollment
Unknown
Registered
2024-12-18
Start date
2024-12-31
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cutaneous squamous cell carcinoma (cSCC)

Interventions

cSCC group:None

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were diagnosed with cutaneous squamous cell carcinoma (including squamous cell tumors in situ and cutaneous squamous cell carcinoma) by skin biopsy;

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Morphological characteristics of scanning images of pathological sections;—

Countries

China

Contacts

Public ContactYingqiu Bao

Beijing Hospital

baoyingqiu0806@126.com+86 10 85133303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026